Despite immense interest in using antimalarials as autophagy inhibitors to treat cancer, it remains unclear whether these agents act predominantly via autophagy inhibition or whether other pathways direct their anti-cancer properties. By comparing the treatment effects of the antimalarials chloroquine (CQ) and quinacrine (Q) on KRAS mutant lung cancer cells, we demonstrate that inhibition of the oxidative arm of the pentose phosphate pathway (oxPPP) is required for antimalarial induced apoptosis. Despite inhibiting autophagy, neither CQ treatment nor RNAi against autophagy regulators (ATGs) promote cell death. In contrast, Q triggers high levels of apoptosis, both in vitro and in vivo, and this phenotype requires both autophagy inhibition and p53-dependent inhibition of the oxPPP. Simultaneous genetic targeting of the oxPPP and autophagy is sufficient to trigger apoptosis in lung cancer cells, including cells lacking p53. Thus, in addition to reduced autophagy, oxPPP inhibition serves as an important determinant of antimalarial cytotoxicity in cancer cells.
INTRODUCTION
Macroautophagy (autophagy) is a evolutionarily conserved lysosomal degradation process that promotes cell survival and metabolic adaptation. 1 In tumors, abundant evidence supports that autophagy operates as a cell survival pathway in response to various micro-environmental stresses as well as promotes resistance to chemotherapy. 2 As a result, there is tremendous clinical interest in inhibiting autophagy as a potential strategy against cancers. Importantly, antimalarials, namely chloroquine (CQ) and hydroxychloroquine (HCQ), inhibit lysosomal function and block the late stages of autophagic proteolysis. Given their long history of clinical use as antimalarials and in diseases such as rheumatoid arthritis, these lysosomotrophic compounds have gained special attention for their potential utility as pharmacological autophagy inhibitors in cancer. 2, 3 Indeed, numerous clinical trials utilizing HCQ in combination with cytotoxic and targeted therapies are under evaluation in various cancers; the first of these studies indicate that HCQ can be successfully used to therapeutically inhibit autophagy in cancer patients with minimal doselimiting toxicities. [4] [5] [6] [7] [8] [9] [10] Despite these initial positive results, much remains to be learned about how antimalarials like HCQ may be best exploited therapeutically against cancer. Notably, although the current prevailing view is that the anti-cancer effects of HCQ predominantly arise from macroautophagy inhibition, multiple preclinical studies suggest that the chemosensitizing effects of this lysosomotrophic agent may not be entirely autophagydependent. 11, 12 Hence, further elucidating the pathways by which antimalarials target cancer cells remains a subject of immense therapeutic significance.
Similar to CQ and HCQ, the antimalarial quinacrine (Q) exhibits anti-cancer properties and has been demonstrated to function as a late-stage autophagy inhibitor. [13] [14] [15] [16] Remarkably, in gastrointestinal stromal tumors, we previously found that Q was significantly more potent than CQ in inducing the apoptosis of cancer cells, both as a single agent and in combination with the tyrosine kinase inhibitor imatinib. 16 Moreover, others have reported that Q is more potent than CQ in killing glioblastoma multiforme cells. 17 Accordingly, by scrutinizing the phenotypic differences between these two FDA-approved agents, we sought to further mechanistically understand how these antimalarials promote cancer cell death. Here, we demonstrate that inhibition of the oxidative arm of the pentose phosphate pathway (oxPPP) is required to induce apoptosis in KRAS mutant lung cancer cells in response to antimalarial treatment.
RESULTS

Quinacrine (Q) promotes apoptosis of NSCLC cells independently of autophagy inhibition
We focused on KRAS mutant non-small cell lung carcinoma (NSCLC) cells because previous studies indicate that genetic autophagy inhibition impairs the proliferation of RAS-transformed cells, while modestly impacting cell death. [18] [19] [20] [21] [22] Treatment of KRAS mutant A549 and H460 NSCLC cells (both p53 wild type, Supplementary Figure 1A) with either CQ or Q led to the dosedependent accumulation of phosphotidylethanolamine lipidated LC3 (LC3-II), consistent with impaired autophagic flux. Neither of these antimalarials inhibited the levels of ERK/MAPK phosphorylation, indicating that key mitogenic signals downstream of oncogenic Ras activation remained intact ( Figure 1a ). Similar to CQ, Q suppressed the proliferative outgrowth of both A549 and H460 cells (Figures 1b and c). Stable depletion of the essential autophagy regulator ATG7 also reduced autophagosome formation (LC3-II) and proliferative expansion (Figure 1d ), thereby confirming previous studies from our lab and others that genetic autophagy inhibition suppresses KRAS mutant cancer cell proliferation. [18] [19] [20] [21] On the other hand, Q was unique in its ability to induce cell death in both A549 and H460 cells. Upon (d) Growth curves following ATG7 depletion and corresponding immunoblots of LC3-II reduction and ATG7 knockdown. (e, f) Q but not CQ reduces NSCLC cell survival. Cells were treated with 30 μM CQ or 10 μM Q for 24 h. Immunoblotting for cleaved PARP and ELISA for cleaved cytokeratin 18 (cCK18) confirms that Q promotes apoptosis. UT = untreated, STS = 1 μM staurosporine (positive control). All data represent mean ± s.e.m. from three independent experiments. Statistical significance was calculated using Student's t-test for pair-wise comparisons in (b) or by ANOVA followed by Tukey's HSD. *P ⩽ 0.05, **P ⩽ 0.01, ***P ⩽ 0.001.
To assay whether Q triggered tumor cell death in vivo, we compared the effects of CQ and Q treatment on NSCLC xenografts. Both CQ and Q blocked the late stages of autophagy, evidenced by increased numbers of autophagosomes (punctate LC3) and p62 (SQSTM1) aggregates, both of which accumulate upon antimalarial inhibition of autophagy ( Figure 2a ). 1, 23 Notably, in A549 xenografts, we also observed increased necrosis following 14 days of Q treatment compared with control or CQ-treated tumors ( Figure 2b ). Consistent with our in vitro studies, both CQ and Q suppressed proliferation, evidenced by a decrease in tumor cells positive for the mitosis marker, phospho-histone H3 (pHH3). However, only Q treatment promoted apoptosis in A549 xenografts, evidenced by increased cleaved caspase-3 (CC3)-positive tumor cells ( Figures 2c-e ). Furthermore, Q-treated animals exhibited reduced tumor volumes and weights, compared with those treated with vehicle (CNT) and CQ, although these reductions were not statistically significant over 21 days of treatment (Supplementary Fig. 2A ). Similarly, both CQ and Q reduced proliferation in H460 xenografts, whereas Q uniquely induced apoptosis ( Supplementary Figures 2B-D) . Finally, in contrast to the tumor xenografts, we did not observe detectable apoptosis in several normal tissues from CQ-and Q-treated animals, evidenced by the lack of terminal deoxynucleotidyl transferase dUTP nick end labeling and CC3 staining (Supplementary Figure 2E ). Overall, these results indicate that Q is selectively cytotoxic for tumors compared with normal tissues; furthermore, the death-inducing effects of Q in NSCLC cells are mediated, at least in part, by targeting pathways other than autophagy.
OxPPP inhibition is required for antimalarials to induce apoptosis in NSCLC cells In parallel, we evaluated the effects of CQ and Q on glucose metabolism, motivated by our previous work demonstrating that genetic ATG deficiency impairs glucose uptake and glycolytic flux in RAS-transformed fibroblasts and breast cancer cells. 20 Using 13 C-NMR to measure [3-13 C]-lactate produced from [1-13 C]glucose, we unexpectedly observed that Q treatment significantly impaired glycolytic flux in A549 and H460 cells, whereas CQ treatment did not ( Figure 3a ). To extend these results, we measured how antimalarials regulated the oxPPP, a side-branch of glycolysis implicated in biosynthesis, antioxidant response and cell survival. 24 In contrast to CQ, Q potently inhibited the oxPPP ( Figure 3b ) and attenuated the enzymatic activity of glucose-6phosphate dehydrogenase (G6PD), the rate-limiting step of the oxPPP (Figure 3c ). We next interrogated the functional importance of oxPPP inhibition in mediating NSCLC cell death during antimalarial treatment. Treatment of A549 and H460 cells with the pharmacological oxPPP inhibitor, 6-aminonicotinamide (6-AN), induced mild cell death as a single agent. However, upon combining 6-AN with CQ, clonogenic recovery was profoundly reduced and apoptotic PARP cleavage was increased to levels comparable with that achieved with Q ( Figure 3d ). Furthermore, upon RNAi-mediated G6PD depletion, CQ treatment was able to induce cell death in KRAS mutant NSCLC cells (Figures 3e and f). Because these death-promoting effects of G6PD depletion or pharmacological inhibition were only observed upon CQ treatment, we tested whether the simultaneous inhibition of oxPPP and autophagy was sufficient to promote cell death. Indeed, the combined knockdown of ATG7 and G6PD abrogated cell survival and increased apoptotic PARP cleavage in A549 and H460 cells ( Figure 3g and Supplementary Figure 3A and B). We propose that this unique convergence of events upon treatment with Q, but not with CQ, mediates the ability to induce cell death in KRAS mutant NSCLC cells.
Autophagy and the oxPPP each serve distinct functions in mitigating reactive oxygen species (ROS) in cells. 21, 25 Thus, we asked how the combined effects of Q on autophagy deficiency and PPP inhibition modulated ROS. Q treatment led to more pronounced levels of ROS in both A549 and H460 cells compared with control and CQ-treated cells (Figures 4a and b ). Moreover, Q-induced apoptosis was significantly attenuated upon co-treatment with the anti-oxidant N-acetyl cysteine (NAC) (Figures 4c and d) . These results corroborate that increased oxidative stress, which we propose to be secondary to the combined inhibition of autophagy and oxPPP, is an important contributor to Q-mediated cytotoxicity in KRAS mutant NSCLC cells. p53 induction is required for NSCLC cell death in response to antimalarial treatment Previous studies indicate CQ and Q can activate the p53 tumor-suppressor pathway via diverse mechanisms. [13] [14] [15] 26, 27 Indeed, Q treatment led to robust p53 induction in A549 and H460 cells in vitro (Figures 5a and b ) and increased numbers of p53-positive cells were evident in Q-treated A549 and H460 xenografts in vivo (Figures 5c and d) . In contrast, CQ failed to significantly induce p53 in either cell type in vitro or in vivo (Figures 5a-d) . To ascertain the functional significance of p53 induction downstream of Q treatment, we interrogated the effects of antimalarials on the p53-null, KRAS mutant NSCLC cell line, H358 (Supplementary Figure 1A) . Importantly, CQ and Q blocked autophagic flux in H358 similarly to p53 wild-type NSCLC cells (Figure 5e and Supplementary Figure 4A ) and suppressed proliferative outgrowth in vitro ( Figure 5f ). Moreover, Q treatment attenuated mitotic activity (pHH3) in H358 xenografts ( Figure 5g ). Thus, the autophagy-inhibitory and anti-proliferative effects of CQ and Q were not p53-dependent. On the other hand, H358 cells were highly resistant to Q-induced cell death both in vivo ( Figure 5g ) as well as in vitro (Figure 4h ). Furthermore, the stable short hairpin RNA (shRNA)-mediated depletion of p53 in A549 and H460 cells ( Supplementary Figures 4B and C) significantly reversed Q-induced cytotoxicity (Figure 5h ).
Combined inhibition of oxPPP and autophagy is sufficient to elicit lung cancer cell death irrespective of p53 status The tumor suppressor p53 has emerged as an important regulator of glucose metabolism. 28 Intriguingly, recent studies demonstrate that p53 inhibits oxPPP flux by directly binding and inhibiting G6PD. 29 Indeed, co-immunoprecipitation studies confirmed a physical interaction between G6PD and p53 upon Q treatment of NSCLC cells (Figure 6a ). Furthermore, similar to CQ, Q failed to significantly inhibit the oxPPP in H358 cells (Figure 6b ). Remarkably, we did note that Q treatment slightly reduced G6PD activity in these cells (Figure 6c ), suggesting factors other than p53 status may influence Q inhibition of G6PD enzymatic activity. Nonetheless, our results indicated that Q-induced cell death and overall oxPPP inhibition in NSCLC cells were both p53-dependent. As p53 can mediate multiple pro-apoptotic pathways, 28 we evaluated the specific requirement of oxPPP inhibition downstream of p53 by testing whether G6PD knockdown was sufficient to promote antimalarial cytotoxicity in p53-deficient cells. Indeed, G6PD knockdown in H358 cells diminished cell survival and increased apoptotic PARP cleavage following CQ or Q treatment (Figures 6d and e and Supplementary Figure 5A ). Finally, we tested the effects of combined knockdown of G6PD and ATG7 on the viability of H358 cells. Indeed, despite the absence of p53, the concomitant genetic inhibition of oxPPP and autophagy was sufficient to promote the death of H358 cells (Figure 6f and Supplementary  Figures 5B and C) . Thus, the simultaneous genetic targeting of autophagy and the oxPPP was sufficient to trigger apoptosis in lung cancer cells, irrespective of p53 status.
DISCUSSION
Currently, there is immense interest in repurposing antimalarials as autophagy inhibitors to treat cancer. 2, 3 Here, by evaluating the treatment effects of CQ and Q, we provide insight into the mechanisms underlying the anti-tumorigenic properties of these two FDA-approved antimalarial lysosomotrophic agents. First, our results suggest that the ability of antimalarials to suppress proliferation in KRAS mutant lung cancer cells is at least partly due to autophagy inhibition, because genetic autophagy deficiency achieved via ATG knockdown elicits analogous antiproliferative effects. On the other hand, autophagy inhibition in itself does not promote significant apoptosis in KRAS mutant NSCLC cells. Rather, inhibition of the oxPPP cooperates with autophagy inhibition to promote antimalarial cytotoxicity in these cells. In addition, using genetic loss-of-function approaches, we demonstrate that the simultaneous targeting of autophagy and the oxPPP is needed to efficiently trigger the apoptosis of these lung cancer cells.
In contrast to our studies, others have found that autophagy inhibition by itself is sufficient to elicit cancer cell death. For example, the basal breast carcinoma cell line, MDA-MB-468, undergoes robust cell death in response to CQ treatment or ATG knockdown and murine KRAS mutant lung cancers exhibit apoptosis and regression in response to acute ATG7 deletion in vivo. 30, 31 These studies indicate that the cooperation that we have observed between autophagy and oxPPP inhibition during Q treatment may be context-specific. However, as the status of the oxPPP was not specifically examined in these studies, it remains uncertain whether alterations in glucose metabolism or other metabolic susceptibilities predispose these tumors to the deathpromoting effects of autophagy inhibition. Nonetheless, our results indicate that co-targeting the oxPPP may represent a valuable strategy to promote the apoptosis of cancer cells that do not robustly respond to autophagy inhibition alone.
To most effectively scrutinize mechanisms underlying cell death, we have used antimalarials as single agents in this study. In reality, these agents are most commonly being repurposed as chemosensitizers in combination with other therapies; in fact, abundant work in preclinical models supports the rationale for targeting autophagy as a combination strategy in multiple tumor types and in response to diverse chemotherapeutic agents. 2, 3 Moreover, the first early phase clinical trials utilizing HCQ in combination with anticancer therapies have recently been reported in humans; although clinical efficacy was not the primary endpoint of these initial phase I or I/II studies, it is noteworthy that remarkable clinical responses were observed in certain patients with refractory tumors. 4-10 Moreover, a 100% clinical response rate and over 70% complete remission rate was observed in dogs with naturally occurring lymphoma following treatment with doxorubicin combined with HCQ. 4 Given the initial optimism from these clinical trials, a more complete understanding of the mechanisms by which antimalarials induce tumor cell death is crucial for the development of future therapeutic strategies using these agents. On the basis of our findings, we hypothesize that CQ or Q will most effectively induce cancer cell apoptosis when combined with a second treatment modality targeting the oxPPP. Although doselimiting toxicities may hamper direct targeting of the oxPPP in cancer patients, several currently utilized clinical agents are known to suppress glucose metabolism. Accordingly, one can predict that such agents, owing to the resulting decline in oxPPP activity, will similarly cooperate with autophagy inhibitors in promoting cell death. Indeed, support for this concept comes from our previous studies in gastrointestinal stromal tumors; because the tyrosine kinase inhibitor imatinib potently inhibits glucose uptake and glycolytic metabolism in gastrointestinal stromal tumor cells, inhibiting autophagy via ATG knockdown or antimalarials potently synergizes with imatinib to trigger apoptosis and prevent the development of acquired resistance in gastrointestinal stromal tumor. 16 We also demonstrate that the dual blockade of autophagy and oxPPP promotes cytotoxicity regardless of p53 status. These findings may be of particular importance in the treatment of NSCLC and pancreatic ductal carcinomas (PDAC), two highly lethal cancers that commonly harbor oncogenic KRAS mutations in combination with the loss or mutation of p53. Notably, studies in genetically engineered mouse models of KRAS mutant pancreatic cancer have revealed complex interconnections between autophagy and p53 in PDAC progression and tumor metabolism. 32, 33 When p53 inactivation occurs by somatic loss of heterozygosity, autophagy inhibition impairs KRAS-driven PDAC progression; moreover, CQ leads to mitochondrial respiration defects. 33 On the other hand, upon embryonic deletion of p53 in the pancreas, autophagy inhibition via genetic ATG7 deletion or HCQ treatment unexpectedly accelerates the onset of PDAC; remarkably, cells isolated from these rapidly growing tumors exhibit increased levels of both glycolytic and oxPPP intermediates. 32 These results broach the possibility that oxPPP inhibition may be exploited to promote tumor cell death and prevent carcinoma progression in certain PDACs lacking both autophagy and p53.
Finally, as clinical trials go forward, an important challenge is identifying useful biomarkers and surrogates to predict antimalarial response against tumors, especially in the advent of new divalent CQ derivatives, such as Ly-05. 34 Our results suggest that the oxPPP activity may serve as one useful monitor of response in therapeutic regimens using antimalarials. Overall, they highlight the importance of identifying and scrutinizing other biological parameters, not just autophagy inhibition, to more effectively evaluate the utility of antimalarials in the clinical oncology setting.
MATERIALS AND METHODS
Cell culture
The NSCLC lines A549, H460 and H358 were acquired from the American Type Culture Collection (Manassus, VA, USA) and passaged for less than 6 months following resuscitation; cell lines were not authenticated or tested for Mycoplasma contamination. A549 cells were grown in Dulbecco's modified Eagle's medium containing 25 mm glucose (UCSF Cell Culture Facility, San Francisco, CA, USA) supplemented with 10% fetal bovine serum, penicillin and streptomycin. H460 and H358 were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, penicillin and streptomycin. CQ and Q were dissolved in water and cells were treated at the indicated doses. Because Q treatment of cells elicits high levels of autofluorescence, the analysis of cultured cells via fluorescence-based activity assays was not technically feasible. NAC was dissolved directly into tissue culture media at a final concentration of 5 μM and pH was readjusted to 7.4 prior to use.
Antibodies and chemicals
Commercial antibodies include phospho-histone H3 (CST 9701), cleaved caspase-3 Alexa Fluor 488 (CST 9669S), ATG12 (CST 2010) and cleaved PARP (CST 9451) obtained from Cell Signaling Technology (Danvers, MA, USA); phospho-p44/42 MAPK (P-ERK) (44-680G) and p44/42 MAPK (ERK1/2) (13-6200) from Invitrogen (Waltham, MA, USA); ATG7 (sc8668) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); p62/SQSTM1 (GP62C) from Progen Biotechnik (Heidelberg, Germany), tubulin (T6199) from Sigma (St Louis, MO, USA) and p53 DO1 (OP43) from Calbiochem (Billerica, MA, USA); G6PD (ab993) from Abcam (Cambridge, MA, USA); and LC3 5F10 for immunofluorescence (NT0231-00) from Axxora (Farmingdale, NY, USA). For immunoblotting, we used an LC3 antibody, which has been described previously, that is now commercially available (ABC232) from EMD Millipore (Billerica, MA, USA). 35 Chemicals include CQ, Q, 6-AN, NAC, etoposide (Et) and doxorubicin (DX), which were all obtained from Sigma-Aldrich (St Louis, MO, USA); staurosporine (STS) from EMD Chemicals (Gibbstown, NJ, USA); 1-13 C glucose from Cambridge Isotopes (Tewksbury, MA, USA); 1-14 C glucose and 6-14 C glucose from Perkin Elmer (Waltham, MA, USA); and Hoechst from Invitrogen.
shRNA-and siRNA-mediated RNA interference pLKO.1 lentiviral expression plasmids containing shRNAs against ATG7 and ATG12 were purchased from Sigma-Aldrich (Mission shRNA) and shRNA against p53 was purchased from Addgene (plasmid 19119, Cambridge, MA, USA). Viral particles were produced using a third-generation lentiviral packaging system in HEK293T cells. Following infection and drug selection, early passage stable pools of ATG knockdown cells (maximum of five passages) were utilized because extended propagation results in the loss of RNAi-mediated silencing and autophagy inhibition.
The target sequences for hairpins directed against ATG7 (NM_006395) are shATG7 #1 (TRCN0000007584): GCCTGCTGAGGAGCTCTCCA and shATG7 #2 (TRCN0000007587): CCCAGCTATTGGAACACTGTA; the target sequence directed against ATG12 (NM_004707) is shATG12 #1 (TRCN0000007393): TGTTGCAGCTTCCTACTTCAA; and the target sequence directed against p53 (Addgene plasmid 19119) is: CCGACTCCAGT GGTAATCTACTTCAAGAGAGTAGATTACCACTGGAGTCTTTTT.
For siRNA-mediated knockdown, Stealth RNAi oligos against human G6PD (HSS103891 and HSS103892, Waltham, MA, USA) were purchased from Invitrogen and cells were transfected with 100 nM of each oligonucleotide using Oligofectamine (Invitrogen) following manufacturer's instructions.
Cell proliferation, cell death and ROS assays
For growth curves, 1 × 10 4 cells were grown in triplicate in the presence of the indicated treatments. Cells were harvested, stained with trypan blue and live cells were enumerated using a hemocytometer at the indicated timepoints. For studies of cell death, trypan blue exclusion was utilized to quantify cell viability because Q treatment elicits high autofluorescence in Antimalarials and the pentose phosphate pathway cells, which precludes the use of fluorescent-based cell death assays. The caspase-cleaved cytokeratin 18 (cCK18) M30 fragment was measured using the M30 Cytodeath ELISA (P10900) from Diapharma (West Chester Township, OH, USA), according to the manufacturer's protocol; this assay quantitatively measures a stable apoptosis-generated neoepitope in CK-18 (Asp396). Levels of ROS were detected using the ROS-Glo H 2 O 2 luminescence kit (Promega G8820, Madison, WI, USA) according to the manufacturer's protocol.
Immunoblotting
Cells were lysed in RIPA lysis buffer plus 10 mM NaF, 10 mM β-glycerophosphate, 1 mM Na 3 VO 3 , 10 nM calyculin A and protease inhibitors. Lysates were clarified by centrifugation for 15 min at 4°C, and protein concentrations were assessed using a bicinchoninic acid protein assay (Thermo, Waltham, MA, USA). Samples containing equal amounts of protein were boiled in sodium dodecyl sulfate sample buffer, resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to polyvinylidene diflouride membrane. Membranes were blocked in phosphate-buffered saline (PBS)+0.1% Tween 20 with 5% nonfat dry milk, incubated with the indicated primary antibodies overnight at 4°C, washed, incubated with horseradish peroxidase-conjugated secondary antibodies and analyzed by enhanced chemiluminescence.
Immunofluorescence and terminal deoxynucleotidyl transferase dUTP nick end labeling analysis
Tumors and normal tissues (lung, liver and small intestine) were harvested, fixed in 4% paraformaldehyde and sent for paraffin embedding and sectioning (4 μM) and hematoxylin and eosin staining at the UCSF Helen Diller Family Comprehensive Cancer Center Mouse Pathology Core. For immunofluorescence staining, slides were subject to heat-induced antigen retrieval using Antigen Unmasking Solution (Citrate-based, Vector Labs, Burlingame, CA, USA) for 20 min at 95°C. Q autofluorescence was not evident in formalin-fixed paraffin-embedded sections. Slides were cooled, blocked in 10% goat serum, followed by overnight primary antibody incubation at 4°C in a humidified chamber. Slides were washed in PBS and incubated with Alexa 488-conjugated secondary antibodies (Invitrogen) for 1 h at 20°C. After washing with PBS, slides were counterstained with Hoechst (2 μg/ml) for 10 min, washed and mounted with Prolong Gold (Invitrogen). Terminal deoxynucleotidyl transferase dUTP nick end labeling assays were performed using ApopTag kits (EMD Millipore) according to the manufacturer's protocol.
Phase and immunofluorescence image acquisition and analysis
Phase images of hematoxylin and eosin sections were acquired on Aperio ScanScope XT (Buffalo Grove, IL, USA) affixed with a × 20 and × 40 objective using Aperio ImageScope software (v11.0.1.725). Immunofluorescence images were acquired on an Axiovert 200 microscope (Carl Zeiss, Pleasanton, CA, USA) equipped with a Spot RT camera (Diagnostic Instruments, Sterling Heights, MI, USA) and a mercury lamp. Images were acquired using MetaMorph software (v6.0, Molecular Devices, Sunnyvale, CA, USA) and arranged using Adobe Illustrator CS5 v15.0.1 (Adobe, San Jose, CA, USA). 13 
C-NMR acquisition and analysis
Cells were grown in Dulbecco's modified Eagle's medium containing 25 mmol/l of [1-13 C] glucose to 80% confluency, upon which medium was collected for NMR analysis and cells were harvested for protein quantification using the bicinchoninic acid assay. Briefly, medium was lyophilized and reconstituted in 1 ml of deuterium oxide. To acquire 13 C spectra, the reconstituted sample was acquired on a 600-MHz INOVA spectrometer (Varian, Palo Alto, CA, USA) using a 30°flip angle, 3.5-s repetition time and broadband proton decoupling. Analysis of the NMR spectra was performed using Bruker Topspin software version 3.0 (Bruker Biospin GmbH, Ettlingen, Germany). The concentrations of metabolites were determined with respect to an external reference, 2,2,3,3-tetradeutero-3-(trimethylsilyl)propionic acid, with a known concentration.
Analysis of oxPPP
One million cells were plated onto 10-cm dishes in triplicate, grown overnight and treated with vehicle control (water) or with CQ or Q at the indicated doses for 3 h at 37°C. Cells were washed twice with PBS and the tissue culture media was replaced with media containing 0.8 μCi of 1-14 Cglucose (Perkin Elmer, Akron, OH, USA) or 6-14 C-glucose containing vehicle (water) or the indicated antimalarial agent; cells were incubated for an additional 7 h prior to analysis. To capture gaseous 14 CO 2 , Whatman filter paper was taped to the inside of culture dish lid and the plate was then sealed with Parafilm; the experiment was terminated by adding 500 μl of perchloric acid to the cells; the plate was resealed and left in the incubator overnight. Filter papers were then carefully removed and placed into vials containing Ready-Safe Liquid Scintillation Fluid (Beckman Coulter, Indianapolis, IN, USA), and 14 CO 2 activity was measured on a Beckman LS6000 Liquid Scintillation Analyzer. The incubation of cells with 6-14 Cglucose, used to correct for 14 CO 2 production from the citric acid cycle, yielded minimal 14 CO 2 activity. G6PD activity assay G6PD activity was determined using the G6PD activity assay kit from Biovision (Milpitas, CA, USA). Cells (1 × 10 6 ) were grown overnight in triplicate on 10-cm dishes and either treated with CQ or Q at the indicated doses or left untreated for 16 h. Cells were washed in cold PBS and cells were harvested in 0.5 ml of lysis buffer as described above. Protein concentration was quantified using the Pierce BCA assay (Rockford, IL, USA); samples were normalized to protein concentration before analysis with the G6PD activity kit according to the manufacturer's instructions.
Antimalarial treatment of lung cancer xenografts
Animal studies were conducted in accordance with approved UCSF Institutional Animal Care and Use Committee Protocols. Xenografts were established in 4-week-old nu/nu male mice (Simonsen Laboratories, Gilroy, CA, USA) by rear flank subcutaneous injection of 1 × 10 6 (H460), 4 × 10 6 (A549) or 10 × 10 6 (H358) cells in a 1:1 dilution of Matrigel (BD Biosciences, San Jose, CA, USA). Tumors were grown to 0.5 cm (maximal dimension) and animals were randomized prior to starting antimalarial treatment. Mice were randomized to receive CQ, Q or vehicle (water) daily. CQ was administered at 60 mg/kg via intraperitoneal injection, Q at 50 mg/kg by oral gavage and vehicle (water) by oral gavage as previously described. 16 Tumors were evaluated for autophagosome (punctate LC3) and p62/ SQSTM accumulation, apoptosis and proliferation following 14 days of treatment. For quantification of imaging data from tissue sections, 10 fields were randomly chosen prior to quantification. Analysis of tumor growth in tumor-bearing mice treated with CQ, Q or vehicle (water) was performed in parallel; the dimensions of tumors were measured using calipers, and tumor volume was calculated using the formula: (length × width 2 )/2. Following 21 days of treatment, mice were killed and individual tumors were weighed. No statistical method was used to predetermine sample size, and no data were excluded.
Statistical analyses
Each experiment was repeated at least three independent times and no data were excluded for analysis. GraphPad Prism software (v5.0b) was used for generation of graphs and statistical analysis. P-values were determined by Student's t-test for pair-wise comparisons or by ANOVA followed by Tukey's HSD for multiple comparisons as indicated. For statistical comparisons, all data exhibited a normal distribution and the variance between groups was similar.
